Abstract. MHC class I-related chain molecules A and B (MICA and B) expressed on the cell-surface of tumor cells are ligands for an activating receptor, NKG2D, expressed on natural killer (NK) cells and stimulate the NK cell-mediated cytotoxicity. On the other hand, the soluble form of MICA and B produced by proteolytic cleavage of cell-surface MIC interferes with NK cell-mediated cytotoxicity. We investigated effect of sodium valproate (VPA), a histone deacetylase inhibitor, on the production of cell-surface and soluble MICA and B and NK cell-mediated cytotoxicity in four human osteosarcoma cells. VPA at 0.5 and 1.0 mM induced acetylation of histones bound to MICA and B gene promoters, increased cell-surface but not soluble MICA and B, and augmented the susceptibility of osteosarcoma cells to NK cell-mediated cytotoxicity. The present results indicate that VPA sensitizes human osteosarcoma cells to cytotoxicity of NK cells.
Introduction
Tumor cells express MHC class I-related chain molecules A and B (MICA and B) on their cell-surface which are the ligands of an activating receptor, NKG2D, expressed on the cell-surface of natural killer (NK) cells. Binding of NK cells to tumor cells through interaction between NKG2D and MICA or B induces cytolysis of tumor cells (1, 2) . Tumor cells also produce the soluble form of MICA and B by proteolytic cleavage of cell-surface MICA and B. Soluble MICA and B interfere with interaction between tumor and NK cells to prevent NK cell-mediated cytotoxicity (1) (2) (3) . Therefore, in order to augment the susceptibility of tumor cells to NK cell cytotoxicity, it is necessary to increase the expression of cell-surface MICA and B or to decrease the production of the soluble form of MICA and B.
It has been shown that gene expression is regulated by acetylation and deacetylation of histones catalyzed by histone acetyltransferase and histone deacetylases (HDACs), respectively. HDAC inhibitors which alter the histone acetylation status have been shown to induce cell cycle arrest and apoptosis in various tumor cells (4, 5) . In addition, HDAC inhibitors stimulate the expression of cellsurface MICA and B on tumor cells to enhance cytotoxicity of NK cells and host immune surveillance against tumor cells (6) (7) (8) (9) (10) (11) .
In the case of osteosarcoma, HDAC inhibitors enhance the susceptibility to Fas-ligand-induced cell death, indicating that host immune defense against osteosarcoma cells is also strengthened by HDAC inhibitors (12) (13) (14) . However, whether the susceptibility of osteosarcoma cells to cytotoxicity of NK cells in the presence of HDAC inhibitors is due to altered production of cell-surface MICA and B or their soluble forms is not clear. In this study, we attempted to clarify this issue using sodium valproate (VPA) as an HDAC inhibitor. VPA was chosen since it has long been used for treatment of epilepsy and bipolar disorder without serious side effects (15, 16) .
Materials and methods
Cells. MG-63, HOS, U-2 OS and SaOS-2 human osteosarcoma cells were cultured as described previously (13 5 cells/dish, respectively, in 10-cm tissue culture dishes containing 5 ml of medium per dish. After 24 h (day 0), cells were cultured further in medium with 0, 0.5 and 1.0 mM VPA. On day 3, half of cultures were analyzed for soluble MICA and B and viable cells. The other half of cultures exchanged fresh medium with or without VPA and were cultured further, and soluble MICA and B and viable cells were measured on day 7. Viable cells were determined by the trypan blue exclusion test. For the assay of soluble MICA and B, after centifugation at 300 x g for 5 min, the medium was analyzed for MICA or B using a DuoSet ® ELISA Development System for human MICA or B (R&D Systems) and a microplate reader (Bio-Rad, Tokyo, Japan). The effect of VPA on the production of soluble MICA and B was evaluated by determining the amount of soluble MICA and B per 10 4 viable cells in VPA-treated cultures as percentage of the average value in untreated cultures.
Cytotoxicity assay. Cytotoxicity of NK cells against HOS, U-2 OS and SaOS-2 osteosarcoma cells was analyzed using a CytoTox-Fluor™ Cytotoxicity Assay kit (Promega, Madison, WI, USA), according to the manufacturer's instructions. Osteosarcoma target cells (T) were cultured in medium with or without 0.5 or 1.0 mM VPA for 7 days. Then, the NK cell cytotoxicity assay was carried out by incubating these cells with NK-92 effector cells (E) at various T:E ratios (1/20-1/5) for 3 h at 37˚C. In blocking experiments, NK-92 cells were cultured in medium with 1.0 μg/ml of purified anti-human NKG2D antibody (BioLegend) for 16 h before incubating with target cells. The number of dead cells was estimated by measuring the activity of proteases in medium which was released from dead cells. The protease activity in medium released spontaneously from target cells and the total maximum protease activity released from all target cells by treatment with 1% Triton X-100 were also determined. The percentage of target cells killed by NK-92 cells was calculated as follows: 100 x (sample protease activity -spontaneously released protease activity)/(total maximum protease activityspontaneously released protease activity).
Chromatin immunoprecipitation (ChIP) assay. The ChIP assay was carried out using an EZ-Magna ChIP TM kit (Millipore, Billerica, MA, USA) according to the manufacturer's instructions. U-2 OS and SaOS-2 cells were cultured in medium with or without 0.5 mM or 1.0 mM VPA for 7 days. After cross-linking of proteins bound to DNA with formaldehyde, nuclear lysate containing protein-DNA complexes was prepared from these cells. An aliquot of the nuclear lysate was used to immunoprecipitate acetylated histone-DNA complexes with anti-acetyl-histone H3 rabbit polyclonal antibody. DNA was extracted from the precipitated acetylated histone-DNA complexes and from another aliquot of nuclear lysate. MICA and MICB gene promoter sequences were amplified by polymerase chain reaction (PCR) using Takara Ex Taq™ DNA polymerase (Takara Bio Inc., Ohtsu, Shiga, Japan) and the following primers; sense, 5'-GCTTATGAAGTTGGAGCTGT-3', and antisense, 5'-AGCCAGAAGCAGGAAGAC-3', for MICA promoter, and sense, 5'-TCAGCTACTCGGGGCTGGTC-3', and antisense, 5'-ACGGCCAGAAACAGCAGGAC-3', for MICB promoter. The PCR conditions were 94˚C for 1 min, 53˚C for 1 min, and 72˚C for 1 min for 35 cycles for MICA gene promoter, and 94˚C for 1 min, 64˚C for 1 min, and 72˚C for 1 min for 35 cycles for MICB gene promoter. The amplified fragments were resolved by electrophoresis in a 1.5% agarose gel and detected by ethidium bromide staining.
Statistical analysis. Data were presented as a mean ± SE. Data of 3 groups or more were analyzed by the two-tailed Dunnett's t-test for multiple comparison. A P-value of <0.05 was considered significant.
Results
Effect of VPA on the expression of MICA/B and HLA class I on the surface of osteosarcoma cells. MG-63, HOS, U-2 OS and SaOS-2 cells were cultured in the presence or absence of VPA at 0.5 or 1.0 mM for 3 or 7 days and the expression of cell surface MICA/B and HLA class I was examined by flow cytometry. All four osteosarcoma cell lines expressed MICA/B and HLA class I on their cell surface (Fig. 1) . VPA at 0.5 mM increased MICA/B-positive cells in U-2 OS and SaOS-2 cells on day 3 and in all four osteosarcoma cells on day 7, while VPA at 1.0 mM increased MICA/B-positive cells in all four osteosarcoma cells on days 3 and 7 (Fig. 2) . The increases in MICA/B-positive cells in the presence of 0.5 and 1.0 mM VPA on day 7 were 1.4-2.3-and 2.3-5.5-fold, respectively.
VPA at 0.5 and 1.0 mM did not increase HLA class Ipositive cells in MG-63 cells on days 3 and 7, but significantly increased these cells in HOS cells on day 3, in U-2 OS cells on days 3 and 7, and in SaOS-2 cells on day 7 (Fig. 3) .
Effect of VPA on acetylation of histones bound to MICA and MICB gene promoters. To determine whether upregulation of MICA and MICB expression by VPA is associated with acetylation of histones bound to the promoters of the MICA and MICB genes, the ChIP assay was carried out using U-2 OS and SaOS-2 cells. The results showed that VPA at 0.5 and 1.0 mM enhanced acetylation of histones bound to the MICA and MICB promoters (Fig. 4) . and B, all four osteosarcoma cells were cultured in the presence of VPA at 0.5 or 1.0 mM for 7 days, and soluble MICA and B accumulated in medium during the first 3 days and the next 4 days were assayed. We found that soluble MICA levels were essentially unchanged in MG-63 and SaOS-2 cells on days 3 and 7, but markedly decreased in HOS and U-2 OS cells on day 7 in the presence of 0.5 or 1.0 mM VPA (Fig. 5) . No soluble MICB was detected in MG-63 cells with or without VPA on days 3 and 7. Soluble MICB levels were decreased on days 3 and 7 in HOS and SaOS-2 cells, and on day 7 in U-2 OS cells in the presence of 0.5 or 1.0 mM VPA (Fig. 5) .
Effect
Effects of VPA on the susceptibility to NK cell-mediated cell death. HOS, U-2 OS and SaOS-2 cells were cultured for 7 days in the presence of 0.5 and 1.0 mM VPA and susceptibility to cytotoxicity of NK-92 NK cells was examined. Treatment with VPA at 0.5 and 1.0 mM was found to increase the susceptibility of these three osteosarcoma cells to NK-92 cells (Fig. 6) . Pretreatment of NK-92 cells with NKG2D-blocking antibody completely prevented the cytotoxic activity of NK-92 cells against all three target cells treated with 1.0 mM VPA (Fig. 6 ).
Discussion
In this study, we showed that VPA elevated the expression of MICA and B on the surface of osteosarcoma cells and enhanced their susceptibility to the cytotoxicity of NK cells as reported with other tumor cells (6) (7) (8) (9) (10) (11) . On the other hand, levels of soluble MICA and B were not changed or rather decreased in the presence of VPA. In human hepatoma cells, VPA has been reported to increase the production of soluble MICA and B (7) . Soluble MICA and B are produced by cleavage of cell-surface MICA and B by proteases including matrix metalloproteinases (1, 2) . Another report has revealed that this cleavage depends on conformational changes of MIC catalyzed by Erp5 disulfide-isomerase (17) . We have investigated whether matrix metalloproteinases participated in production of soluble forms. Our preliminary data showed that VPA decreased mRNAs of some matrix metalloproteinases in osteosarcoma cells (data not shown). Although further studies are needed, it is possible that VPA has effects on the expression of matrix metalloproteinases in osteosarcoma and hepatoma cells. We reported previously that VPA at 0.5 and 1.0 mM increased the amount of acetylated histones in MG-63, HOS, U-2 OS and SaOS-2 osteosarcoma cells (13) . In this study, the chromatin immunoprecipitation assay revealed that VPA enhanced the acetylation of histones bound to MICA and B promoters. Since acetylation status of histones is closely related to gene regulation (4, 5) , it is possible that the modification of DNA-bound histones described above caused increased expression of cell-surface MICA and B in osteosarcoma cells.
HLA class I molecules suppress the activity of NK cells through inhibitory receptors (1, 18) . In this study, VPA increased the expression of HLA class I in osteosarcoma cells, particularly in U-2 OS cells. However, VPA also increased the susceptibility of U-2 OS cells to the cytotoxicity of NK cells. These results suggest that the effect of VPA on the amount of cell-surface MICA and B is greater than that on the amount of HLA class I in osteosarcoma cells.
Pretreatment of NK cells with the NKG2D-blocking antibody reduced the cytotoxic activity of NK cells on osteosarcoma cells pretreated with 1.0 mM VPA to levels less than that on osteosarcoma cells without pretreatment. These results suggest that the VPA-induced increase in the expression of NKG2D ligands is involved in increased susceptibility of osteosarcoma cells to NK cells. Human NKG2D ligands consist of not only MICA and B but also 1,2) . Therefore, VPA likely enhances the susceptibility of osteosarcoma cells to these cytotoxic immune cells. VPA has also been shown to enhance the susceptibility of osteosarcoma cells to Fas-ligand-induced cell death (13) . These results suggest that VPA in combination with immunotherapy activating cytotoxic immune cells could be useful to treat osteosarcomas.
